Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 68

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 68
---
     |              |         — |     |        |         — |     |               |         — |     |                           |  20,930 |     |                               |         — |     |           |    71,243 |
| Christopher Jewell, Ph.D.(7)   |     | 2024 |     |        | 411,923 |     |              |         — |     |        |   513,612 |     |               |   524,476 |     |                           | 218,400 |     |                               |    19,343 |     |           | 1,687,754 |
| Chief Scientific Officer       |     | 2023 |     |        |  37,500 |     |              |         — |     |        |         — |     |               |         — |     |                           |  15,600 |     |                               |         — |     |           |    53,100 |

(1) These amounts represent actual earnings for the calendar year, which may be impacted by, among other things, hire date and the timing of any salary increases made during the year.

(2) These amounts include a one-time bonus of $75,000 for Dr. Brunn for efforts to deliver the positive topline data for the Company’s DISSOLVE I and DISSOLVE II Phase 3 clinical trials and retention bonuses.

(3) Represents the aggregate grant date fair value of stock and option awards computed in accordance with ASC Topic 718, excluding the effect of estimated forfeitures. For a description of the assumptions used in valuing these awards, see Note 13 to our consolidated audited financial statements included in our 2024 Annual Report.

(4) Represents amounts earned under our annual performance-based bonus program. For additional information, see “—Performance Bonuses” below.

(5) For Dr. Brunn, the amount for 2024 includes $966 representing payments on Dr. Brunn’s term life insurance policy and $1,200 representing reimbursement for cell phone expenses. The amount for 2023 includes $2,383,268 for settlement of outstanding awards as of November 13, 2023 in connection with the Merger and $965 representing payments on Dr. Brunn’s term life insurance policy. For Mr. Davis, the amount for 2024 includes $966 representing payments on Mr. Davis’ term life insurance policy, $900 representing reimbursement for cell phone expenses, $10,350